

CURRICULUM VITAE
Jason M Foster, MD

CAMPUS ADDRESS: Department of Surgical Oncology
986880 Nebraska Medical Center
Omaha, NE 68198-6880
Phone: (402) 559-8941
Email: jfosterm@unmc.edu

EDUCATION

1986 - 1990	BS, Chemistry, Bucknell University
1990 - 1994	MD, Medicine, Temple University School of Medicine

POST DEGREE TRAINING

1994 - 2002	Intern/Resident, General Surgery, Case Western Reserve University (CWRU)/University Hospital of Cleveland, Cleveland, OH
1996 - 1999	Fellow, Allen Scholar Basic Science Research Fellowship, CWRU, Cleveland, OH
2002 - 2004	Fellow, Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY
2004 - 2005	Fellow, Gastrointestinal & Mixed Tumor Oncology, Roswell Park Cancer Institute, Buffalo, NY

CONTINUING EDUCATION AND TRAINING

2002 - 2003	Interventional Endoscopy
2002 - 2003	Radiofrequency Ablation Techniques
2003 - Present	Sentinel Lymph Node Technique
2010 - Present	Single Site Laparoscopic Surgery
2013 - Present	Robotic Surgery Training

ACADEMIC APPOINTMENTS

2020 - Present	Full Professor of Surgery, Department of Surgical Oncology, University of Nebraska Medical Center (UNMC), Omaha, NE
2010 - Present	Adjunct Associate Professor of Surgery, Department of Surgical Oncology, Creighton University, Omaha, NE
2010 - 2020	Associate Professor of Surgery, Department of Surgical Oncology, University of Nebraska Medical Center (UNMC), Omaha, NE
2006 - 2010	Assistant Professor of Surgery, Department of Surgical Oncology, Creighton University, Omaha, NE
2002 - 2006	Clinical Instructor, Department of Surgery, State University of New York at Buffalo, Buffalo, NY
2000 - 2002	Affiliate Clinical Instructor, Department of Surgery, CWRU, Cleveland, OH

1996 - 2000 Adjunct Clinical Instructor, Department of Surgery, CWRU, Cleveland, OH

CERTIFICATIONS AND LICENSES

1992 Board Certification/Surgery, USMLE I
1993 Board Certification/Surgery, USMLE II
1995 Board Certification/Surgery, USMLE III
2004 - 2024 American Board of Surgery 48798
1996 - 2005 Ohio Medical License 35-07-1662-F
2002 - 2007 New York Medical License 225358-1
2005 - 2020 Nebraska Medical License 23497

GRANTS AND CONTRACT SUPPORT

Active

Title: Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer
ID Number: 5R01CA247763-02
Funding Agency: DHHS/NIH/NCI
Project Period: 2020 - 2025
Total Dollars: \$1,875,291
Direct Cost: \$284,644
Role: Co Investigator (Rachagani)

Completed

Title: Improving the Extraction of Health-Promoting Bioactive Nutrients from Agricultural Commodities of Economic Importance to Nebraska
ID Number: 26-6221-0315-002
Funding Agency: University of Nebraska - Lincoln
Project Period: 2016 - 2018
Total Dollars: \$75,000
Direct Cost: \$75,000
Role: Principal Investigator

OTHER APPOINTMENTS AND POSITIONS

1987 - 1989 Summer Internship/Chemist, Mobay Chemical Corporation, Pittsburgh, PA
1994 - 2002 Resident, Department of General Surgery, CWRU, Cleveland, OH
1996 - 1999 Flight Surgeon, Department of Surgery, Metrohealth Medical Center/Case Western Reserve University, Cleveland, OH
1997 - 1999 Surgeon, Department of Surgery, SUMMA Health Systems, Akron, OH
2002 - 2004 Fellow, Department of Surgical Oncology, Roswell Park Cancer Institute,

	Buffalo, NY
2006 - 2014	General Surgeon, Surgery, Dept of Veterans Affairs NE-Western IA Health Care System, Omaha, NE, United States
2017 - Present	Medical Director - 8th Flr Werner Cancer Cntr Inpatient Unit, Nebraska Medicine, Omaha, NE, USA

HONORS AND AWARDS

Local

1990	Temple University Scholars, Physiology, Temple University Scholars, Philadelphia, Pennsylvania
2008	Promising Young Physician, Creighton University Medical Center (CUMC), Omaha, NE
2016	Nominated for the Harold and Beverly Maurer Award, NE
2019	UNeMed Research Innovation New Invention Notification (NIN), UNeMed, Omaha, NE
2019	Caring Kind Award Nominee

National

1995	Invitation to Molecular Biology Workshop, AACR
1996-1998	NIH K-12 Research Oncology Training Grant, National Institutes of Health (NIH)
1998-1999	NIH K-12 Translation Research Oncology Research Grant, NIH
1999	Outstanding Young Americans
2016	Donald Morton Award from Journal of Surgical Oncology
2017	ASPEN-2017 National Meeting Abstract of Distinction, ASPEN-2017
2020	ACT/SSO abstract SSO/ACPM Travel Award, Society of Surgical Oncology
2022	ACT/SSO abstract SSO/ACPM Travel Award, Society of Surgical Oncology

Regional

1996-1999	Dudley P. Allen Scholar Fellow, CWRU, Department of Surgery, Cleveland, Ohio
1997	2nd Place Abstract/Presentation, 36th Annual Cleveland Surgical Society, Cleveland, Ohio
2008-present	Patient's Choice Award Physicians

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

1990 - Present	Member, Student National Medical Association
1995 - Present	Member, American Association for Cancer Research (AACR)
2000 - Present	Member, American Medical Association (AMA)
2001 - Present	Member, American College of Surgeons (ACS)
2002 - Present	Member, Society of Surgical Oncology (SSO)
2003 - Present	Member, American Society of Clinical Oncology (ASCO)

2004 - Present	Member, National Medical Association
2005 - Present	Member, Creighton Medical Society
2006 - Present	Member, North Central Cancer Treatment Group
2010 - Present	Member, Southwestern Surgical Congress
2010 - Present	Member, Association for Academic Surgery
2012 - Present	Fellow, American College of Surgeons (ACS)

COMMITTEE ASSIGNMENTS

Local/Regional

1997 - 1998	Instructor, CWRU Advanced Anatomy for 4th-year Students
1997 - 1999	Co-president, Minority House Staff Organization
1998 - 1999	Delegate, Graduate Medical Education Council
1998 - 1999	President, Association of Residents and Fellows
1998 - 2000	Delegate, Student National Medical Association (SNMA)
2006 - 2008	Member, CUMC Committee on Cancer
2007 - 2010	Member, CUMC Education Environment Task Force Committee
2007 - 2010	Member, Creighton Hospital Pharmacy and Therapeutics Anticoagulation Committee
2008 - 2010	Member, CUMC Colorectal Community Task Force for Screening and Prevention
2018 - Present	Mortality Review Committee
2018 - Present	Member, MD/PhD Advisor Committee J. Carmichael
2018 - Present	Physician Advisory Group for Patient Experience (PAGPE) Committee
2018 - 2018	Capstone Mentor & Advisor Committee (K. Brown) MS/MBA Candidate
2020 - Present	Community Outreach & Engagement FPBBC Advisory Board
2020 - Present	Physician Champion, Department of Surgery Nebraska Foundation
	Grateful Patient Program, University of Nebraska Medical Center
2021 - Present	Internal Advisory Board (IAB) for FPBCC

National/International

2008 - Present	Member, Board of Directors, My Sister's Keeper Breast Cancer Survivors
2010 - Present	Session Moderator, Regional Cancer Therapies
2016 - Present	Education and Meeting Planning Committee, Regional Cancer Therapies
2018 - Present	ECOG Surgical Committee HIPEC section clinical trial development
2018 - Present	PSOGI International Consensus Guidelines Participant. US Peritoneal Metastasis Consensus Guidelines for Clinical Management
2018 - 2018	Course Director, Regional Cancer Therapies National Meeting
2019 - Present	Board of Directors, Mesothelioma Applied Research Foundation

UNMC

2010 - Present	High School Alliance Student Shadowing Program
2010 - 2010	Department of Surgery, Promotion and Tenure Committee, University of Nebraska Medical Center
2016 - Present	Committee on Cancer, University of Nebraska Medical Center
2017 - 2018	Ophthalmology Chairman Search Committee, University of Nebraska

	Medical Center
2017 - 2018	Department of Surgery, Promotion and Tenure Committee, University of Nebraska Medical Center
2019 - 2020	Member, Culture and Inclusivity Task Force for Perioperative Services

MISCELLANEOUS

2018	Facilitator, Resident Seminar/Case Conference; Topic - Desmoid/Carcinomatosis/HIPEC, University of Nebraska Medical Center
2021	Section Editor, Section Editor for JSO Seminar: Surgeons Establishing the Landscape of Cotemporary Clinical Trials in Oncology, JSO
2005 - Present	ad hoc Reviewer, Cancer
2005 - Present	ad hoc Reviewer, Hernia Journal
2007 - Present	ad hoc Reviewer, Annals of Surgical Oncology
2007 - Present	ad hoc Reviewer, European Journal of Surgical Oncology
2007 - Present	ad hoc Reviewer, World Journal of Surgical Oncology
2007 - Present	ad hoc Reviewer, Asian-Pacific Journal of Hematology & Oncology
2008 - Present	ad hoc Reviewer, European Journal of Cancer
2010 - Present	Editorial Board, Journal of Surgical Oncology
2010 - Present	ad hoc Reviewer, Tumor Biology
2015 - Present	Invited, Editorial Board, Journal of Surgery and Operative
2016 - Present	Editorial Board, Annals of Surgical Oncology
2019 - Present	ad hoc Reviewer, World Journal of Surgery
2019 - 2019	Invited Panelist, Discuss the Prodigy 7 (French) Clinical Trial CRS vs CRS/HIPEC in Colon Cancer, Regional Cancer Therapies 2019, Bethesda, MD

PRESENTATIONS

1. foster jm. Contextual effects of TGF-beta on the tumorigenicity of human colon carcinoma. Surgical Grand Rounds, University Hospital of Cleveland, CWRU; 1997
2. foster jm. The role of TGF-alpha in colon cancer tumorigenesis and progression. Surgical Grand Rounds, University Hospital of Cleveland, CWRU; 1998
3. foster jm. Management of function and non-functional neuroendocrine tumors of the pancreas. Oncology Lecture Series MetroHealth Medical Center, CWRU; 1999
4. foster jm. Current management of congenital tracheal-esophageal fistulas. Pediatric Grand Rounds, Cleveland Clinic/MetroHealth Medical Center, CWRU; 2000
5. foster jm. total mesorectal excision in the management of rectal cancer is superior to conventional resection with radiation. Oncology Lecture Series MetroHealth Medical Center, CWRU; 2001
6. foster jm. Current management of gallbladder: What have the past 50 years taught us?. RPCI Surgical Grand Rounds; 2003
7. foster jm. The role of brachytherapy for sarcoma management. RPCI Medical & Surgical Oncology Joint Lecture Series; 2004
8. foster jm. Surgical management of hepatic neuroendocrine disease in the new millennium. RPCI Surgical Grand Rounds; 2004

9. foster jm. Current management of gallbladder: What have the past 50 years taught us?. State University of Buffalo, Department of Surgery; 2004
10. foster jm. Advances in breast cancer that have revolutionized the management of the disease. 4th Annual Women Issues in the 21st Century, Creighton University; 2005 Oct 7
11. foster jm. Innovations in surgical oncology - hyperthermic therapy. Creighton University, Department of Surgery Grand Rounds; 2006 Jun 12
12. foster jm. Contemporary management of melanoma & sarcoma. Keynote Speaker, Metro Omaha Coders' Association (MOCA), Creighton University; 2006 Nov 10
13. foster jm. The prevention and management of skin and colon cancer. Senior Partner Seminar, Creighton University; 2007 Jan 27
14. foster jm. Updates in colorectal cancer detection and treatment. 2nd Annual Surgical Techniques for Primary Care Physicians, Creighton University; 2007 Feb 9
15. foster jm. Diagnosis and management of Gastric and Pancreatic Cancer. Senior Partner Seminar; 2007 Jun 23. Creighton University
16. foster jm. Diagnosis and Management of Melanoma and Colorectal Cancer. Offutt Air Force Base Family Practice Grand Rounds; 2008 Feb 6
17. foster jm. Translational research in surgical oncology. Creighton University, Department of Surgery Grand Rounds; 2008 May 19
18. foster jm. The prevention and management of colorectal cancer. Creighton Community Health Center Health Fair; 2008 Jun 13
19. foster jm. Common cancer in women: Prevention, screening, and management. Women's Health Conference; 2008 Jun 21
20. foster jm. Contemporary screening strategies in oncology. Creighton Community Health Center Seminar; 2008 Jul 11
21. foster jm. Translational research: MUC-2 in PMP & EGFR mutations in mesothelioma. Creighton University, Department of Surgery Presentation to Visiting Professor Timothy R. Billiar, MD; 2008 Jul 21
22. foster jm. Chair, Round Table Discussion on the Contemporary Management of Breast Cancer. My Sister's Keeper Annual Breast Cancer Survivor Banquet, Invited; 2008 Oct
23. foster jm. The Current Role of CRS/IPHC in the Management of Appendix and Colorectal Peritoneal Surface Disease, Invited. UNMC 4th Annual Thoracic and GI Conference; 2009 Sep 30. University of Nebraska Medical Center
24. foster jm. Contemporary Management of Peritoneal Surface Malignancies - Part I (Appendix & Colorectal Cancer). UNMC Grand Rounds; 2009 Dec 16. University of Nebraska Medical Center
25. foster jm. Introduction to Peritoneal Surface Malignancies. UNMC OR Staff Education Conference; 2010 Mar 17. University of Nebraska Medical Center
26. foster jm. Introduction to Peritoneal Surface Malignancies. UNMC ICU Staff Education conference; 2010 Apr 7 & 8. University of Nebraska Medical Center
27. foster jm. Contemporary Management of Peritoneal Surface Malignancies - Part I (Appendix & Colorectal Cancer). CUMC Grand Rounds; 2010 Apr 17. Creighton University, Omaha, NE
28. foster jm. Introduction to Peritoneal Surface Malignancies. UNMC OR Peri-operative Staff Education Conference; 2010 Apr 7 & 8. University of Nebraska Medical Center
29. foster jm. Introduction to Peritoneal Surface Malignancies. UNMC Oncology Nursing Staff Education Conference; 2010 Apr 7 & 8. University of Nebraska Medical Center

30. foster jm. Role of EGFR in Hepatocellular and Mesothelioma Abdominal Carcinomas. Department of Surgery Weekly Research Forum; 2010 May 26
31. foster jm. Management of Patients with Peritoneal Surface Malignancies. AORN Quarterly Meeting Nebraska Chapter; 2011 Feb 9
32. foster jm. Management of Patients with Peritoneal Surface Malignancies. Infuscience Home Health Education Conference; 2011 Feb 15
33. foster jm. Contemporary Management of Peritoneal Surface Malignancies. UNMC OB-Gyn Grand Rounds; 2011 Mar 6
34. foster jm. Innovations in Management of Peritoneal Surface Malignancies, Invited. Optum Conference; 2011 Jul 26
35. foster jm. Peritoneal Surface Malignancies Ripe for Research, Invited. UNMC Pathology Grand Rounds; 2012 Mar 3. University of Nebraska Medical Center
36. foster jm. Innovations in Management of Peritoneal Surface Malignancies. UNMC Oncology Nursing Fellowship Education; 2012 Mar 5. University of Nebraska Medical Center
37. foster jm. Innovations in Management of Peritoneal Surface Malignancies. UNMC Retired Physician Breakfast; 2012 Apr 11. University of Nebraska Medical Center
38. foster jm. Foraging the Frontiers of Peritoneal Surface Malignancies. Wisconsin Surgical Club; 2012 May 14
39. foster jm. Peritoneal Surface Malignancies from a 'Peritonealist's' Perspective: Optimization of Management & Opportunities for Translational Research. University of Maryland Oncology Grand Rounds, Visiting Professor; 2012 Jun 25
40. foster jm. The Role of Home Health Care in Improving Patient Outcomes. Annual Bioscrip National Meeting, Invited Speaker; 2012 Oct 2
41. foster jm. Homestart TPN - Keeping Patients Out of the Hospital with Cost Effective HHS. Annual Infuscience/UNMC Transplant & Oncology Meeting, Invited Speaker; 2013 May 9
42. foster jm. Innovations in the Management of PSM $\tilde{\phi}$ CRS & HIPEC. UNMC Patient Outreach & Development Lecture Series; 2013 Sep 24. University of Nebraska Medical Center
43. foster jm. Surgical Management of Appendiceal Tumors. 8th Annual UNMC Thoracic & GI Oncology Conference; 2013 Oct 4. University of Nebraska Medical Center
44. foster jm. Regional Cancer Therapies in the Management of Metastasis - Another Example of Personalized Therapy. Marshall University Surgery Grand Rounds, Invited Speaker; 2013 Oct 02. University of Nebraska Medical Center
45. foster jm. Era of Personalized Oncology. UNMC Medical Student Surgical Society Interest Group, Invited Speaker; 2014 Feb 4. University of Nebraska Medical Center
46. foster jm. Regional Cancer Therapies in the Management of Metastasis - Another Example of Personalized Therapy. The Nebraska State Assembly of the Association of Surgical Technologists (NESA AST) Winter Assembly; 2014 Mar 1
47. foster jm. Role of Adjuvant or Neoadjuvant Targeted Therapy in Peritoneal Mesothelioma: Is It Time to Study This?. International Symposium on Malignant Mesothelioma, Invited Speaker; 2014 Mar 7
48. foster jm. Contemporary Management of Cutaneous Melanoma. UNMC Family Medicine Grand Rounds; 2014 Mar 23. University of Nebraska Medical Center
49. foster jm. Personalized Therapy in Advanced Malignancies: Indications and Utility of

- Regional Surgical Therapies. UNMC 5-West Staff Education Conference; 2014 Jul 11. University of Nebraska Medical Center
50. foster jm. Contemporary Management of Cutaneous Melanoma. UNMC Surgery Grand Rounds; 2014 Jul 16. University of Nebraska Medical Center
 51. foster jm. Role of HIPEC in Peritoneal Mesothelioma Management. International Symposium on Malignant Mesothelioma, Invited Panel Discussion Leader; 2015 Mar 7
 52. foster jm. Personalized Surgical Therapy in Advanced and Metastatic Cancer. American Academy of Professional Coders - AAPC Quarterly Meeting, Invited Speaker; 2015 May 19
 53. foster jm. Utilizing Cytoreductive Surgery in the Management of Colorectal Cancer. UNMC 10th Annual Thoracic & GI Oncology Conference, Invited Speaker; 2015 Oct 9. Omaha, NE
 54. foster jm. Contemporary Management of Cutaneous Melanoma. UNMC Plastic Surgery Grand Rounds; 2016 Feb 10. University of Nebraska Medical Center
 55. foster jm. Peritoneal Metastasis Management: A Field Rooted in Personalized Care & Robust with Research Opportunities. Medical College of Wisconsin Oncology Grand Rounds, Invited Speaker; 2016 Feb 26
 56. foster jm. Skin Cancer Diagnosis, Management, and Coding. American Academy of Professional Coders - AAPC Quarterly Meeting; 2016 Mar 15
 57. foster jm. Personalized Surgical Therapy in Advanced and Metastatic Cancer. Nebraska Association of Nurse Anesthetists (NANA) Meeting; 2016 Apr 9
 58. foster jm. Contemporary Management of Cutaneous Melanoma, Advances in Primary, Nodal and Advanced Disease. Nebraska Association of Nurse Anesthetists (NANA) Meeting; 2016 Apr 9
 59. foster jm. Peritoneal Metastasis: A Field Rooted in Personalized Care and Robust with Research Opportunities. Pathology and Microbiology Clinical Grand Rounds, Invited Speaker; 2016 May 4. University of Nebraska Medical Center, Omaha, NE
 60. foster jm. ICU Management Considerations in Cytoreductive Surgery & HIPEC. UNMC ICU Staff Education Conference; 2016 May
 61. foster jm. Peritoneal Mesothelioma Selection, Preparation, and Factors in Outcome. Leader, International Symposium on Malignant Mesothelioma; 2016 May 20. Houston, TX
 62. foster jm. Peritoneal Metastasis Management: A Field Rooted in Personalized Care & Robust with Research Opportunities including Advance Reconstruction. Plastic Surgery Grand Rounds, Invited Speaker; 2016 Jun 10. University of Nebraska Medical Center, Omaha, NE
 63. foster jm. The Management of Nodal Disease and the Positive Sentinel Node in Cutaneous Melanoma. 1st Annual Melanoma Conference: Diagnosis, Therapy & Prognosis; 2016 Sept 16
 64. foster jm. Evaluation and Indication: Cytoreduction-HIPEC for GI Peritoneal Metastasis. 11th Annual Fall Midwest Thoracic & GI Oncology Conference; 2016 Oct 06
 65. de Rosa, N; Hein, N; Smith, J; Foster JM; Dimaio, D; Marr, A; Kozel, J; Wahl, A; Thayer, S; Silva-Lopez E. A Contemporary Nomogram for the Prediction of Lymph Node Metastasis in Melanoma (oral). Society of Surgical Oncology (SSO) Annual Cancer Symposium; 2017. Seattle, WA
 66. foster jm. Management of Peritoneal Surface Malignancies: Surgical Cytoreduction &

- HIPEC. Strong Ovarian Cancer Survivors (SOCS) Group Meeting (Ovarian cancer support group); 2017 Jan 19
67. yanala, u; adams, s; ocken, l; skiendziel, p; boikins, t; foster, jason. Safety and Efficacy of HomeStart Parenteral Nutrition (poster). ASPEN Annual Meeting 2017; 2017 Feb 18 -21
 68. foster, jason; sleightholm, rl; hall, b; shostrom, v; smith, l. Validating the safety of CRS-HIPEC through a NSQIP comparative outcomes analysis (oral). 12th International Symposium on Regional Cancer Therapies; 2017 Feb 18 - 20. Snowbird, UT
 69. foster jm; Sleightholm R; Burt J; Watley D; Wahlmeier S; Patel A. VTE Event Rates in Cytoreductive Surgery: A Retrospective, Single Institute Comparison of Dextran vs Heparin (poster). 12th International Symposium on Regional Cancer Therapies; 2017 Feb 18 - 20. Snowbird, UT
 70. foster jm. Peritoneal Mesothelioma Patient Preparation, Surgical Selection, and Factors in Outcome. International Symposium on Malignant Mesothelioma; 2017 Mar 25. Bethesda, MD
 71. foster jm. Exploring the Role of Mucins in Peritoneal Metastasis. International Symposium on Malignant Mesothelioma; 2017 Mar 26. Bethesda, MD
 72. foster jm. Post-operative Care of Complex Gastrointestinal Surgical Patients. Invited Speaker, Nursing Staff Education Day; 2017 May 9. Nebraska Medicine/UNMC - Fred and Pamela Buffet Cancer Center
 73. foster jm. Post-operative Care of Complex Gastrointestinal Surgical Patients. Invited Speaker, Oncology Nursing Fellowship Program; 2017 Nov 7. Nebraska Medicine/UNMC - Fred and Pamela Buffet Cancer Center
 74. foster jm. Post-operative Care of Complex Gastrointestinal Surgical Patients. Invited Speaker, Oncology Nursing Fellowship Program; 2018 Apr 13. Nebraska Medicine/UNMC - Fred and Pamela Buffet Cancer Center
 75. foster jm. Is CRS & HIPEC a Safe and Effective Palliative Treatment Strategy in Patients with Refractory Symptomatic Peritoneal Metastasis?. Invited Speaker, 35th Annual Meeting of the Society for Thermal Medicine; 2018 May 10. Tuscon, AZ
 76. Foster JM. Comparative Analysis Among Centers, Outcome Analysis. 2018 International Symposium on Malignant Mesothelioma; 2018 June 08. Minneapolis, MN
 77. foster jm. Post-operative Care of Complex Gastrointestinal Surgical Patients. Invited Speaker, Oncology Nursing Fellowship Program; 2018 Sep 11. Nebraska Medicine/UNMC - Fred and Pamela Buffet Cancer Center
 78. foster jm. Peritoneal Surface Malignancies (PSM): Dispelling Misperceptions and Exploring the Contemporary Application of CRS/HIPEC in PSM Management. Surgery Grand Rounds; 2018 Oct 10. University of Nebraska Medical Center
 79. foster jm. Proposed US CRS vs CRS/HIPEC Clinical Trial in Colon Cancer Peritoneal Disease, Invited Presenter. 2019
 80. Malhotra GK; Patel A; Bethea M; Brown K; foster jm. The Safety and Utility of Intraoperatively Placed Central Lines Maintained During Postoperative Recovery in Complex Gastrointestinal Surgery (Poster, Oral Quick Shot). 14th International Symposium on Regional Cancer Therapies; 2019 Feb 16. Phoenix, AZ
 81. Malhotra GK; Patel A; Bethea M; Brown K; foster jm. Evidence of Extra-peritoneal Systemic Efficacy of HIPEC with Carboplatin, (Poster, Oral quick shot). 14th International Symposium on Regional Cancer Therapies; 2019 Feb 16. Phoenix, AZ
 82. Patel A; Malhotra GK; Bethea M; Brown K; Foster JM. CRS & HIPEC is a Safe and

- Effective Palliative Treatment Strategy in Patients with Refractory Symptomatic Peritoneal Metastasis, (Oral). 14th International Symposium on Regional Cancer Therapies; 2019 Feb 17. Phoenix, AZ
83. Enke T; Fingeret A; Are C; Vargas L; foster jm; Ly Q; Padussis J; Shivaswamy V; Singh S; Boerner B. Immediate Dysglycemia After Pancreatic Resection: Prevalence and Risk Factors, Poster. ENDO 2019 Endocrine Society Meeting; 2019 Mar 23. New Orleans, LA
 84. Malhotra GK; Patel A; Bethea M; Brown K; foster jm. The Safety and Utility of Intraoperatively Placed Central Lines Maintained During Postoperative Recovery in Complex Gastrointestinal Surgery (Poster). Society of Surgical Oncology (SSO) Annual Cancer Symposium; 2019 Mar 28. San Diego, CA
 85. Patel A; Malhotra GK; Bethea M; Brown K; Foster JM. CRS & HIPEC is a Safe and Effective Palliative Treatment Strategy in Patients with Refractory Symptomatic Peritoneal Metastasis, (Poster). Society of Surgical Oncology (SSO) Annual Cancer Symposium; 2019 Mar 28. San Diego, CA
 86. foster jm. Discuss the Prodigy 7 (French) Clinical Trial CRS vs CRS/HIPEC in Colon Cancer, Invited Panelist. 14th International Symposium on Regional Cancer Therapies; 2019 Mar 25. Bethesda, MD
 87. Foster JM. Peritoneal Surgery Trials. 2019 International Symposium on Malignant Mesothelioma; 2019 Mar 25. Bethesda, MD
 88. foster jm. Post-operative Care of Complex Gastrointestinal Surgical Patients. Nursing Fellowship Program; 2019 Apr 10. Fred and Pamela Buffet Cancer Center, Omaha, NE
 89. foster jm. Post-operative Care of Complex Gastrointestinal Surgical Patients. Invited Speaker, Oncology Nursing Fellowship Program; 2019 Sept 27. Nebraska Medicine/UNMC - Fred and Pamela Buffett Cancer Center
 90. foster jm. Contemporary appendix cancer management has been established through personalized care and poise for progress in precision medicine. Keynote Speaker, Appendiceal Cancer & PMP Symposium; 2019 Oct 01. University of Utah - Huntsman Cancer Institute
 91. foster jm. Peritoneal Surface Malignancies (PSM): Dispelling Misperceptions and Exploring the Contemporary & Future Application of CRS/HIPEC in PSM Management. Department of Surgery Grand Rounds; 2019 Oct 02. University of Utah - Huntsman Cancer Institute
 92. Foster JM. Post-operative Care of Complex Gastrointestinal Surgical Patients. Invited Speaker, Oncology Nursing Fellowship Program; 2020 Feb 27. Nebraska Medicine/UNMC - Fred and Pamela Buffett Cancer Center
 93. Zhang M; Plambeck B; Tu A; Shostrom V; Brown K; Cushman-Volkoun A; Swanson B; Foster JM. Expanded Mutation Profiling in Appendix Peritoneal Metastasis Has Prognostic and Therapeutic Utility When Managed with Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. International Symposium on Advanced Cancer Therapies International Symposium; 2020 Feb
 94. Zhang M; Mikus R; Hegeholz D; Shostrom V; Mathews A; Commers J; Lambert L; Foster JM. Carboplatin Hyperthermic Intraperitoneal Chemotherapy is Safe and Efficacious in Recurrent and Advanced Ovarian Cancer. International Symposium on Advanced Cancer Therapies International Symposium; 2020 Feb
 95. Zhang M; Chandra SR; Moore M; DiMaio D; Shostrom V; Commers J; Lambert L; Foster JM. Exploring Head and Neck Melanoma Sentinel Lymph Node Outcome Compliance

- with Multicenter Selective Lymphadenectomy Trials Predicted Outcome. International Symposium on Advanced Cancer Therapies International Symposium; 2020 Feb
96. Foster JM. CATCH Trial in Colon Cancer Peritoneal Disease. (Invited). 2020 Advanced Cancer Therapies International Symposium; 2020 Feb
 97. Foster JM. Post-operative Care of Complex Gastrointestinal Surgical Patients. Nursing Staff Education Day, Invited Speaker; 2021 Apr 21. Fred and Pamela Buffett Cancer Center, Omaha, NE
 98. Foster JM. Post-operative Care of Complex Gastrointestinal Surgical Patients. Nursing Fellowship Program, Invited Speaker; 2021 Sep 21. Fred and Pamela Buffett Cancer Center, Omaha, NE
 99. Tu A; Zhang C; McDermot S; Igbinigie I; Craig M; Shostrom V; Foster JM. Prior Surgery a Potential Modifiable Risk Factor in Appendiceal Cancer Peritoneal Metastasis contributing to Genitourinary Implantation and Outcome, Poster Presentation. Annual ACS Clinical Congress Symposium; 2021 Oct. Virtual
 100. Tu A; Zhang C; McDermot S; Igbinigie I; Craig M; Shostrom V; Foster JM. Prior Surgery a Potential Modifiable Risk Factor in Appendiceal Cancer Peritoneal Metastasis contributing to Genitourinary Implantation and Outcome, Poster Presentation. Annual SSO/ACT Symposium; 2022 Mar. Dallas, TX
 101. Hegeholtz D; Zhang C; Brown K; Shostrom V; Foster JM. Exploring the utility of incisional Negative Pressure Wound Therapy (NPWT) in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy CRS/HIPEC in reduction of SSI and readmissions, a single center retrospective study. Annual SSO/ACT Symposium; 2022 Mar. Dallas, TX
 102. Foster JM. Post-operative Care of Complex Gastrointestinal Surgical Patients, (Invited Speaker). Nursing Staff Education Day; 2022 Mar 29. Fred and Pamela Buffett Cancer Center, Omaha, NE
 103. Foster JM. Colon Cancer HIPEC Trial Update (Invited Speaker). ACT/SSO International Symposium; 2022 Mar. Dallas, TX

PUBLICATIONS

A. ARTICLES PUBLISHED IN SCHOLARLY JOURNALS

1. Jiang D, Yang H, Willson JK, Liang J, Humphrey LE, Zborowska E, Wang D, Foster J, Fan R, Brattain MG. Autocrine transforming growth factor provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states. *Journal of Biological Chemistry*. 273 : 31471-31479. 1998
2. Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JK. Contextual effects of transforming growth factor β on the tumorigenicity of human colon carcinoma cells. *Cancer Research*. 59 : 4725-4731. 1999
3. Hurd TC, James T, Foster JM. Factors that affect breast cancer treatment: underserved and minority populations. *Surg. Oncol. Clin. N. Am.* 14 : 119-30, vii. 2005
4. Javle MM, Yu J, Khoury T, Chadha KS, Chadha KC, Iyer RV, Foster J, Kuvshinoff BW, Gibbs JF, Geradts J, Black JD, Brattain MG. Akt expression may predict favorable prognosis in cholangiocarcinoma. *Journal of Gastroenterology and Hepatology*

- (Australia). 21 : 1744-1751. 2006
5. Palesty JA, Foster JM, Hurd TC, Watroba N, Rezaishiraz H, Edge SB. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. *Journal of Surgical Oncology*. 93 : 129-132. 2006
 6. Foster JM, Litwin A, Gibbs JF, Intengen M, Kuvshinoff BW. Diagnosing Regenerative Nodular Hyperplasia, the "Great Masquerader" of Liver Tumors. *Journal of Gastrointestinal Surgery*. 10 : 727-733. 2006
 7. Milind M. Javle; Jihnhee Yu; Thaer Khoury; Krishdeep S. Chadha; Renuka V. Iyer; Jason Foster; Boris W. Kuvshinoff; John F. Gibbs; Joseph Geradts; Jennifer D. Black; Michael G. Brattain. Erratum. *Journal of Gastroenterology and Hepatology (Australia)*. 22 : 145. 2007
 8. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligg S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G, Society of Surgical Oncology Annual Meeting. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin. *Annals of Surgical Oncology*. 14 : 128-133. 2007
 9. Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. *Cancer Research*. 67 : 665-673. 2007
 10. Foster JM, Hoshi H, Gibbs JF, Iyer R, Javle M, Chu Q, Kuvshinoff B. Gallbladder cancer. *Annals of Surgical Oncology*. 14 : 833-840. 2007
 11. Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. *Annals of Surgical Oncology*. 14 : 752-758. 2007
 12. Foster JM, Filocamo P, Nava H, Schiff M, Hicks W, Rigual N, Smith J, Loree T, Gibbs JF. The introducer technique is the optimal method for placing percutaneous endoscopic gastrostomy tubes in head and neck cancer patients. *Surg Endosc*. 21 : 897-901. 2007
 13. Gatalica Z, Foster JM, Loggie BW. Low grade peritoneal mucinous carcinomatosis associated with human papilloma virus infection. *Croatian Medical Journal*. 49 : 669-673. 2008
 14. Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. *Annals of Surgical Oncology*. 16 : 152-158. 2009
 15. Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK, Loggie BW. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. *World J Surg Oncol*. 8 : 88. 2010

16. Lynch HT, Snyder C, Davies JM, Lanspa S, Lynch J, Gatalica Z, Graeve V, Foster J. FAP, gastric cancer, and genetic counseling featuring children and young adults. *Familial Cancer*. 9 : 581-588. 2010
17. Gupta PK, Turaga KK, Miller WJ, Loggie BW, Foster JM. Determinants of outcomes in pancreatic surgery and use of hospital resources. *Journal of Surgical Oncology*. 104 : 634-640. 2011
18. J. Esquivel; R. Sticca; P. Sugarbaker; E. Levine; T. D. Yan; R. Alexander; D. Baratti; D. Bartlett; R. Barone; P. Barrios; S. Bieligm; P. Bretcha-Boix; C. K. Chang; F. Chu; Q. Chu; S. Daniel; E. Debre; M. Deraco; L. Dominguez-Parra; D. Elias; R. Flynn; J. Foster; A. Garofalo; F. N. Gilly; O. Glehen; A. Gomez-Portilla; L. Gonzalez-Bayon; S. Gonzalez-Moreno; M. Goodman; V. Gushchin; N. Hanna; J. Hartmann; L. Harrison; R. Hoefer; J. Kane; D. Kecmanovic; S. Kelley; J. Kuhn; J. Lamont; J. Lange; B. Li; et al. Erratum. *Annals of Surgical Oncology*. 18 : 2011
19. Foster JM, Gupta PK, Carreau JH, Grotz TE, Blas JV, Gatalica Z, Nath S, Loggie BW. Right hemicolectomy is not routinely indicated in pseudomyxoma peritonei. *Am Surg*. 78 : 171-7. 2012
20. Dhir M, Crockett DG, Stevens TM, Silberstein PT, Hunter WJ, Foster JM. Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature. *Clin Sarcoma Res*. 4 : 8. 2014
21. K. Turaga; E. Levine; R. Barone; R. Sticca; N. Petrelli; L. Lambert; G. Nash; M. Morse; R. Adbel-Misih; H. R. Alexander; F. Attiyeh; D. Bartlett; A. Bastidas; T. Blazer; Q. Chu; K. Chung; L. Dominguez-Parra; N. J. Espat; J. Foster; K. Fournier; R. Garcia; M. Goodman; N. Hanna; L. Harrison; R. Hoefer; M. Holtzman; J. Kane; D. Labow; B. Li; A. Lowy; P. Mansfield; E. Ong; C. Pameijer; J. Pingpank; M. Quinones; R. Royal; G. Salti; A. Sardi; P. Shen; J. Skitzki; J. Spellman; J. Stewart; J. Esquivel; et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. *Annals of Surgical Oncology*. 21 : 1501-1505. 2014
22. Richard L. Sleightholm; James R. Willcockson; Duncan C. Watley; Frederick L. Durden; Jason M Foster. Bilateral lymphatic spread of metastatic basal cell carcinoma. *Plastic and Reconstructive Surgery - Global Open*. 4 : 2016
23. Foster JM, Sleightholm RL, Wahlmeier S, Loggie B, Sharma P, Patel A. Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis. *World J Surg Oncol*. 14 : 243. 2016
24. Sleightholm RL, Willcockson JR, Watley DC, Durden FL, Foster JM. Bilateral Lymphatic Spread of Metastatic Basal Cell Carcinoma. *Plast Reconstr Surg Glob Open*. 4 : e1182. 2016
25. Sleightholm R, Wahlmeier S, Carson JS, Drincic A, Lazenby A, Foster JM. Massive adrenal vein aneurysm mimicking an adrenal tumor in a patient with hemophilia A: a case report and review of the literature. *Journal of Medical Case Reports*. 10 : 1-6. 2016
26. Foster JM, Sleightholm R, Watley D, Wahlmeier S, Patel A. The Efficacy of Dextran-40 as a Venous Thromboembolism Prophylaxis Strategy in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Am Surg*. 83 : 134-140. 2017
27. DeFoe A, Heckman A, Slater D, Silva-Lopez E, Foster J, Bowden T, Vargo C. A

- Single-Center Experience With Isolated Limb Infusion: An Interventional Oncology Opportunity. *AJR Am J Roentgenol.* 208 : 663-668. 2017
28. Hall B, Padussis J, Foster JM. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis. *Surg. Clin. North Am.* 97 : 671-682. 2017
 29. Foster JM, Sleightholm R, Smith L, Ceelen W, Deraco M, Yildirim Y, Levine E, Muñoz-Casares C, Glehen O, Patel A, Esquivel J. Re: The American Society of Peritoneal Surface Malignancies Multi-Institution Evaluation of 1,051 Advanced Ovarian Cancer Patients Undergoing Cytoreductive Surgery and HIPEC: An Introduction of the Peritoneal Surface Disease Severity Score. *Journal of Surgical Oncology* 2016;114(7):779-784. *J Surg Oncol.* 118 : 720. 2018
 30. Jason S. Long; Jason M. Foster; Jeffrey S. Cooper. The use of hyperbaric oxygen therapy to treat an anaerobic retroperitoneal abscess with extension into the mediastinum. *American Surgeon.* 85 : E524-E526. 2019
 31. Jason M Foster; Richard Sleightholm; Asish Patel; Valerie Shostrom; Bradley Hall; Beth Neilsen; David Bartlett; Lynette M Smith. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures. *JAMA network open.* 2 : e186847. 2019
 32. Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S, List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. *Eur J Surg Oncol.* 2019
 33. Kaushik G, Seshacharyulu P, Rauth S, Nallasamy P, Rachagani S, Nimmakayala RK, Vengoji R, Mallya K, Chirravuri-Venkata R, Singh AB, Foster JM, Ly QP, Smith LM, Lele SM, Malafa MP, Jain M, Ponnusamy MP, Batra SK. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. *Oncogene.* 40 : 848-862. 2020
 34. K. Govaerts; R. J. Lurvink; I. H.J.T. De Hingh; K. Van der Speeten; L. Villeneuve; S. Kusamura; V. Kepenekian; M. Deraco; O. Glehen; B. J. Moran; Pedro Barrios-Sanchez; Joel M. Baumgartner; Almog Ben-Yaacov; Rosella Bertulli; Peter Cashin; Tom Cecil; Sanjeev Dayal; Michele De Simone; Jason M. Foster; Diane Goere; Kuno Lehmann; Yan Li; Brian W. Loggie; Faheez Mohamed; David L. Morris; Aviram Nissan; Pompiliu Piso; Marc Pocard; Beate Rau; Marc A. Reymond; Lucas Sideris; John D. Spiliotis; Victor J. Verwaal; e. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. *European Journal of Surgical Oncology.* 2020
 35. S. Kusamura; V. Kepenekian; L. Villeneuve; R. J. Lurvink; K. Govaerts; I. H.J.T. De Hingh; B. J. Moran; K. Van der Speeten; M. Deraco; O. Glehen; Pedro Barrios-Sanchez; Joel M. Baumgartner; Almog Ben-Yaacov; Rosella Bertulli; Peter Cashin; Tom Cecil; Sanjeev Dayal; Michele De Simone; Jason M. Foster; Diane Goere; Kuno Lehmann; Yan Li; Brian W. Loggie; Faheez Mohamed; David L. Morris; Aviram Nissan; Pompiliu Piso; Marc Pocard; Beate Rau; Marc A. Reymond; Lucas Sideris; John D. Spiliotis; Victor J. Verwaal; e. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. *European Journal of Surgical Oncology.* 2020
 36. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface

- malignancies: Palliative care considerations. Cancer. 2020
37. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Standards. Cancer. 2020
38. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer. 2020
39. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. Cancer. 2020
40. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. Cancer. 2020
41. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors. Cancer. 2020
42. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer. 2020
43. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. Cancer. 2020
44. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Cancer. 2020
45. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors. Ann. Surg. Oncol. 2020
46. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann. Surg. Oncol. 2020
47. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann. Surg. Oncol. 2020
48. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Ann. Surg. Oncol. 2020
49. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Ann. Surg. Oncol. 2020
50. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. Ann. Surg. Oncol. 2020
51. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Ann. Surg. Oncol. 2020
52. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. Ann. Surg. Oncol. 2020
53. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Standards. Ann. Surg. Oncol. 2020
54. Chicago Consensus Working Group. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction. Annals of Surgical Oncology. 27 : 1737-1740. 2020
55. Kiran Turaga; Nita Ahuja; H. Richard Alexander; Daniel E. Abbott; Brian Badgwell; Joel M. Baumgartner; M. Haroon A. Choudry; James C. Cusack; Jeremiah L. Deneve; Jesus Esquivel; Jason M. Foster; Nader Hanna; Andrea Hayes-Jordan; Fabian M. Johnston; Daniel M. Labow; Laura A. Lambert; Byrne Lee; Edward A. Levine; Andrew M. Lowy; Garrett M. Nash; Charles Staley; Konstantinos I. Votanopoulos; Maheswari Senthil; Paul H. Sugarbaker; S. Diane Yamada; David L. Bartlett. The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction. Cancer. 126 : 2510-2512. 2020

56. Cole KE, Ly QP, Hollingsworth MA, Cox JL, Stromnes IM, Padussis JC, Foster JM, Vargas LM, Talmadge JE. Comparative phenotypes of peripheral blood and spleen cells from cancer patients. *International Immunopharmacology*. 85 : 2020
57. Foster JM, Patel A, Zhang C, Shostrom V, Brown K, Cushman-Vokoun AM. Investigating the utility of extended mutation analysis in gastrointestinal peritoneal metastasis. *Journal of surgical oncology*. 122 : 1106-1113. 2020
58. Stewart JH, Blazer DG, Calderon MJG, Carter TM, Eckhoff A, Al Efishat MA, Fernando DG, Foster JM, Hayes-Jordan A, Johnston FM, Lautz TB, Levine EA, Maduekwe UN, Mangieri CW, Moaven O, Mogal H, Shen P, Votanopoulos KI. The Evolving Management of Peritoneal Surface Malignancies. *Current problems in surgery*. 58 : 100860. 2021
59. John H. Stewart; Dan G. Blazer; Maria Jose Godoy Calderon; Taylor M. Carter; Austin Eckhoff; Mohammad A. Al Efishat; Deemantha G. Fernando; Jason M. Foster; Andrea Hayes-Jordan; Fabian M. Johnston; Timothy B. Lautz; Edward A. Levine; Ugwuji N. Maduekwe; Christopher W. Mangieri; Omeed Moaven; Harveshp Mogal; Perry Shen; Konstantinos I. Votanopoulos. *The Evolving Management of Peritoneal Surface Malignancies. Current Problems in Surgery*. 2021
60. Chunmeng Zhang; Benjamin D. Plambeck; Margaret E. Craig; Alexander Tu; Ryan J. Mikus; Valerie Shostrom; Sean P. McDermott; Ikponmwosa Igbini; Krista Brown; Allison Cushman-Vokoun; Jason M. Foster. Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC. *Journal of Surgical Oncology*. 123 : 1599-1609. 2021
61. Kathryn E. Cole; Quan P. Ly; Michael A. Hollingsworth; Jesse L. Cox; James C. Padussis; Jason M. Foster; Luciano M. Vargas; James E. Talmadge. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis. *Cellular Immunology*. 363 : 2021
62. Watanabe-Galloway S, Kim J, LaCrete F, Samson K, Foster J, Farazi PA, LeVan T, Napit K. Cross-sectional survey study of primary care clinics on evidence-based colorectal cancer screening intervention use. *The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association*. 2021
63. Foster JM, Alexander HR, Zhang C. Regional therapy trials in peritoneal metastases: The path to standardization of care: Introduction. *Journal of surgical oncology*. 125 : 55-56. 2022
64. Foster JM, Maithel SK. Introduction: Surgeons establishing the landscape of contemporary clinical trials in oncology. *Journal of surgical oncology*. 125 : 5-6. 2022
65. Foster JM, Alexander HR, Zhang C. Regional therapy trials in peritoneal metastases: The path to standardization-Colorectal cancer. *Journal of surgical oncology*. 125 : 57-63. 2022
66. Cole KE, Ly QP, Hollingsworth MA, Cox JL, Fisher KW, Padussis JC, Foster JM, Vargas LM, Talmadge JE. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. *International immunopharmacology*. 106 : 108628. 2022
67. Zhang C, Patel A, Hegeholz D, Brown K, Shostrom V, Pottebaum M, Foster JM. Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis. *Annals of surgical oncology*. 2022
68. Zhang C, Patel A, Hegeholz D, Brown K, Shostrom V, Pottebaum M, Foster JM. ASO Visual Abstract: Cytoreductive Surgery with HIPEC is a Safe and

- Effective, A Palliative, A Option, A in, A Chemo-Refractory, A Symptomatic Peritoneal, A Metastasis. *Annals of surgical oncology*. 2022
69. Foster JM, Zhang C. ASO Author Reflections: Palliative Management of Peritoneal Metastasis Exploring the Risks and Benefits of CRS/HIPEC, a Distinctly Different Context Than Early CRS/HIPEC Intervention With 'Curative Intent'. *Annals of surgical oncology*. 2022

B. ARTICLES ACCEPTED FOR PUBLICATION IN SCHOLARLY JOURNALS

Not Applicable

C. ARTICLES SUBMITTED FOR PUBLICATION IN SCHOLARLY JOURNALS

1. patel, a; cushman-volkoun, a; sleightholm, rl; foster jm. Exploration of mutations in GI cancers with peritoneal metastasis. *Annals of surgical oncology*. 2019
2. foster jm; sleightholm, rl; hall, b; watley, d; broekhuis, j; wahlmeier, s. Outcomes in LG-PMP detected by screening compared to symptom PMP presentation. *Journal of surgical oncology*. 2019; 0022-4790
3. patel, a; kaur, s; sheinin, y; batra, s; foster jm. Evaluation of glycoprotein expression profiles in peritoneal metastases as a potential therapeutic target. *Annals of surgical oncology*. 2019; 1068-9265
4. el-abaseri, t; patel, a; loggie, bw; foster jm. Novel illustration that MUC-2 over-expression promotes tumor growth by autocrine cellular events and signaling. *Journal of surgical oncology*. 2019; 0022-4790
5. Sleightholm RL; Burt J; Watley DC; Wahlmeier S; Patel AD; Foster JM. VTE Event Rates in Cytoreductive Surgery: A Retrospective, Single Institute Comparison of Dextran vs Heparin. *Annals of surgical oncology*. 2019; 1068-9265
6. Yanala UR; Adams S; Ocken L; Skiendziel P; Boikins T; foster jm. Safety and Efficacy of HomeStart Parenteral Nutrition. *Journal of Parenteral and Enteral Nutrition*. 2019
7. sleightholm, RL; Hardie V; Nicholas T; Watley DC; Broekhuis J; Wahlmeier S; foster jm. Defining the Safety of Epidural Pain Control in CRS/HIPEC in Conjunction with VTE Prophylaxis. *Journal of anesthesia*. 2019; 0913-8668
8. Batra S; Kaushik G; Seshacharyulu P; Rauth S; Rachagani S; Nimmakayala RK; Singh A; foster jm; Ly Q; Ponnusamy M. Targeting Pancreatic Cancer Stem Cells: The Potential of Afatinib Inhibiting Stemness and Metastasis. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2019; 1078-0432
9. Long JS; Foster JM; Cooper JS. The Use of Hyperbaric Oxygen Therapy to Treat an Anaerobic Retroperitoneal Abscess with Extension into the Mediastinum. *American Surgeon*. 2019
10. Patel A; Malhotra GK; Bethea M; Brown K; foster jm. CRS and HIPEC is a Safe and Effective Palliative Treatment Strategy in Patients with Refractory Symptomatic Peritoneal Metastasis. *Annals of surgical oncology*. 2019; 1068-9265

D. BOOKS PUBLISHED, IN PREPARATION, SUBMITTED OR IN PRESS

Not Applicable

E. CHAPTERS IN BOOKS

1. Yi B; Foster JM; Loggie BW. Current Clinical Oncology: Intra-peritoneal Cancer Therapy. Humana Press; 2007. "Hyperthermic Intraperitoneal Chemotherapy in Nongynecologic Cancer"
2. Foster JM; Nava H; Hicks W; Gibbs J. Gastrostomy. InTech; 2011. "Indications for pre- or peri- percutaneous endoscopic gastrostomy tubes (PEG) and predictors of prolonged enteral feeding in head and neck cancer patients treated with surgical extirpation"
3. Foster JM; Malhotra G; Patel A. Caring for Patients with Mesothelioma: Principles and Guidelines. Springer; 2018. Chapter 2: History of CRS/HIPEC for peritoneal metastasis and evolution of CRS/HIPEC in the management of peritoneal mesothelioma

F. BOOKS OR JOURNALS EDITED

Not Applicable

G. ABSTRACTS AND PRELIMINARY COMMUNICATIONS

1. Foster JM; Willis J; Brattain MG; Willson JKV. "TGF-alpha overexpression results in in vivo progression of colon cancer cells. 36th Annual Cleveland Surgical Society; 1998
2. Foster JM; Willis J; Brattain MG; Willson JKV. "TGF-alpha overexpression results in in vivo progression of weakly tumorigenic human colon cancer cells". Digestive Disease Week; 1998
3. Foster JM; Willis J; Venkaeswarlu S; Lin Y; Ferguson K; Zboroskwa; Brattain MG; Willson JKV. "Ectopic TGF-alpha expression in colon non-tumorigenic cancer cells results in in vivo progression by induction of angiogenesis, proliferation and the inhibition of apoptosis". 90th Annual AACR Meeting; Philadelphia, Pennsylvania. 1999
4. Hoshi H; Foster JM; Chu Q; Kuvshinoff B; Rajput A; Driscoll D; Nava HR; Gibbs JF. "Radical re-resection is indicated for all T2 and T3 gallbladder and results in the same survival as primarily resected gallbladder cancers". Society of Surgical Oncology Meeting; 2004
5. Foster JM; Hoshi H; Chu Q; Kuvshinoff B; Rajput A; Driscoll D; Nava HR; Gibbs JF. "Radical re-resection is indicated for all T2 and T3 gallbladder and results in the same survival as primarily resected gallbladder cancers". Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI); 2005
6. Palesty JA; Foster JM; Kraybill WG; Banka T; Sheldon DG; Driscoll D; Kane JM. "Melanoma patients and incidence of non-melanoma malignancies". Society of Surgical Oncology (SSO); 2005
7. foster jm; Black J; LeVea C; Kuvshinoff B; Gibbs J; Javle M. COX-2 and EGFR Expression Are Common in Hepatocellular Carcinoma Supporting Biological Targeted Therapy Directed at These Pathways. Winter Gastrointestinal American Society of Surgical Oncology (ASCO-GI); 2005
8. Rajput A; Wang J; Foster JM; Dawson D; Brattain MG; Wilson JKV. "The role of autocrine transforming growth factor alpha in epidermal growth factor receptor mediated tumorigenicity". Society of University Surgeons; 2006

9. Foster JM; Black J; LeVeae C; Khoury T; Kuvshinoff B; Javle M; Gibbs JF. "Cox-2 expression and EGFR expression with downstream pathway activation are prognostic predictors in hepatocellular carcinoma and are potential targets for biological therapies". Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI); 2006
10. Foster JM; Filacoma P; Brady B; Nava H; Hicks W; Rigual N; Loree T; Gibbs JF. "Defining the indications for prophylactic percutaneous endoscopic gastrostomy tubes in head and neck cancer patients". Society of Surgical Oncology (SSO); 2006
11. foster jm; Black J; LeVeae C; Khoury T; Kuvshinoff B; Javle M; Gibbs JF. Cox-2 Expression and EGFR Expression with Downstream Pathway Activation Are Prognostic Predictors in Hepatocellular Carcinoma and Are Potential Targets for Biological Therapies. Oral Plenary Session III Society of Surgical Oncology; 2006
12. Rajput A; Wang J; foster jm; Dawson D; Brattain M; Wilson JKV. The Role of Autocrine Transforming Growth Factor Alpha in Epidermal Growth Factor Receptor Mediated Tumorigenicity. Journal of Surgical Research. 2006 Feb , Vol. 130: 192-193
13. Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW. "Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability (OR) in malignant peritoneal mesothelioma (MPM)". Oral Session American Society of Clinical Oncology (ASCO); 2007
14. foster jm; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW. Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability (OR) in malignant peritoneal mesothelioma (MPM). Oral Session, 2nd International Symposium on Regional Cancer Therapies; 2007
15. foster jm; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW. Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability (OR) in malignant peritoneal mesothelioma (MPM). Oral Session, SSO; 2007
16. foster jm; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW. "Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability (OR) in malignant peritoneal mesothelioma (MPM)". Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI); 2007
17. Foster JM; El-Abaseri T; Loggie BW. "Novel illustration that MUC-2 over-expression promotes tumor growth by autocrine cellular events and signaling". Oral Session Third International Symposium on Regional Cancer Therapies; 2008
18. Foster JM; Grotz TE; Turaga KK; Gatalica Z; Sharma P; Loggie BW. "Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei". Society of Surgical Oncology (SSO); 2008
19. El-Abaseri T; Foster JM; Loggie BW. "MUC-2 over-expression promotes tumor growth by autocrine cellular events and signaling". American Association of Cancer Research (AACR); 2008
20. foster jm; Grotz TE; Turaga KK; Gatalica Z; Sharma P; Loggie BW. Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei. Winter ASCO-GI; 2008
21. foster jm; Grotz TE; Turaga KK; Gatalica Z; Sharma P; Loggie BW. Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei. Oral Session, 3rd International Symposium on Regional Cancer Therapies; 2008
22. foster jm; El-Abaseri T; Loggie BW. Novel Illustration That MUC-2 Over-expression

- Promotes Tumor Growth by Autocrine Cellular Events and Signaling. Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI); 2008
23. Foster JM; Gupta P; Carreau J; Grotz TE; Gatalica Z; Sharma P; Loggie BW. "Routine right hemicolectomy (RHC) may not be indicated in pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN)". Winter Gastrointestinal American society of Clinical Oncology (ASCO-GI); 2009
 24. Foster JM; El-Abaseri T; Loggie BW. "MUC-2 overexpression in colorectal cancer promotes tumor survival by regulation of Caspase-8 and akt expression". Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI); 2009
 25. Lilleberg S; Foster JM; Uppala P; Govindarajan V; Gatalica Z; Loggie BW. "Malignant peritoneal mesotheliomas harbor somatic mutations in EGFR MET, and several Gate-Keeper Genes: Potential predictive and prognostic markers for focused treatment strategies". Society of Surgical Oncology (SSO); 2009
 26. Lilleberg SL; Foster JM; Uppala R; Govindarajan V; Gatlica Z; Loggie BW. "Analysis of pseudomyxomal peritonei and appendiceal adenocarcinomas reveal somatic mutations of key genes within the MAPK, AKT, and WNT signaling pathways: Potential prognostic and predictive markers for focused treatment strategies". American Association of Cancer Research (AACR); 2009
 27. Foster JM; Uppala P; Govindarajan V; Carreau J; Gatalica Z; Lilleberg S; Nath S; Loggie BW. "Novel and existing activating EGFR mutations are predictive of a relative improved survival in malignant peritoneal mesothelioma (MPM) and responsive to EGFR-TK inhibitors (EGFR-TKI)". Oral Session American Society of Clinical Oncology (ASCO); 2009
 28. foster jm; Gupta P; Carreau J; Grotz TE; Gatalica Z; Sharma P; Loggie BW. Routine right hemicolectomy (RHC) may not be indicated in pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). Oral Session, 4th International Symposium on Regional Cancer Therapies; 2009
 29. foster jm; El-Abaseri T; Loggie BW. MUC-2 overexpression in colorectal cancer promotes tumor survival by regulation of Caspase-8 and Akt expression. SSO Annual Meeting; 2009
 30. Lilleberg SL; foster jm; Uppala R; Govindarajan V; Gatalica Z; Loggie BW. Malignant peritoneal mesotheliomas harbor somatic mutations in EGFR, MET, and several gate-keeper genes: Potential predictive and prognostic markers for focused treatment strategies. American Association of Cancer Research (AACR); 2009
 31. foster jm; Uppala P; Govindarajan V; Carreau J; Gatalica Z; Lillleberg S; Nath S; Loggie BW. Novel and existing activating EGFR mutations are predictive of a 'relative' improved survival in malignant peritoneal mesothelioma (MPM) and responsive to EGFR-TK inhibitors (EGFR-TKI). Fourth International Symposium on Regional Cancer Therapies, Oral Session; 2009
 32. Foster JM; Gupta P; Blas JT; Carreau J; Grotz TE; Loggie BW. "Venous thromboembolism prophylaxis with sequential compression devices, early ambulation, and dextran (SEED) is a safe, effective and easily reversible surgical prophylaxis intervention in peritoneal carcinomatosis management". Winter Gastrointestinal American Society of Clinical oncology (ASCO-GI); 2010
 33. Foster JM; Gupta P; Blas JT; Carreau J; Grotz TE; Loggie BW. "Venous thromboembolism prophylaxis with sequential compression devices, early ambulation,

- and dextran (SEED) is a safe, effective and easily reversible surgical prophylaxis intervention in peritoneal carcinomatosis management". Oral Session, 5th International Symposium on Regional Cancer Therapies; 2010
34. Foster JM; Carreau J; Loggie BW. "The utility of laparoscopy in early pseudomyxoma peritonei (PMP)". Oral Session 5th International Symposium on Regional Cancer Therapies; 2010
 35. El-Abaseri T; Thomas P; Loggie BW; Foster JM. "MUC-2 overexpression in colorectal cancer promotes tumor survival by regulation of Caspase-8 and AKT expression". MUC2 Oral Session 5th International Symposium on Regional Cancer Therapies; 2010
 36. Gupta P; Carreau J; Grotz TE; Gatalica Z; Sharma P; Loggie BW; Foster JM. "Routine right hemicolectomy (RHC) may not be indicated in pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN)". South Eastern Surgical Conference; 2010
 37. Gupta P; Blas JT; Carreau J; Grotz TE; Loggie BW; Foster JM. "Venous thromboembolism prophylaxis with sequential compression devices, early ambulation, and dextran (SEED) is a safe, effective and easily reversible surgical prophylaxis intervention in peritoneal carcinomatosis management". South Eastern Surgical Conference; 2010
 38. Gupta PK; Turaga KK; Gupta H; Miller WJ; Loggie BW; Foster JM. "Determinants of resource utilization in pancreatoduodenectomy: A multicenter analysis of 1467 patients". Society of Surgical Oncology (SSO); 2010
 39. Gupta PK; Gupta H; Turaga KK; Miller WJ; Loggie BW; Foster JM. "Predictors of pulmonary and cardiac complications following pancreatoduodenectomy for cancer". Society of Surgical Oncology (SSO); 2010
 40. Foster JM; Uppala P; Govindarajan V; Carreau J; Gatalica Z; Lilleberg S; Nath S; Loggie BW. "Novel and existing activating EGFR mutations are predictive of a 'relative' improved survival in malignant peritoneal mesothelioma (MPM) and response to EGFR-TK inhibitors (EGFR-TKI)". Oral Session 10th Annual Mesothelioma Foundation Meeting; 2010
 41. Foster JM. "Role of neoadjuvant chemotherapy in carcinomatosis arising from high-grade appendix adenocarcinoma". Oral Session 6th International Symposium on Regional Cancer Therapies; 2011
 42. Bodkin T; Burke A; Skiedziel P; Tanner J; Foster JM. Collaboration Between Referring Providers and Home Infusion Company Clinicians Can Improve Outcomes and Avoid Hospital Admissions for Patients Requiring Home Parenteral Nutrition and May Represent a Safe, More Cost Effective Strategy. ASPEN Clinical Nutrition Meeting; 2012
 43. El-Abaseri T; Brattain M; Howell G; Foster JM. "Extracellular mucin MUC-2 promotes colon cancer growth and transformation in non-mucinous and mucinous cancer cells". Regional Cancer Therapies; 2013
 44. Foster JM; Subbiah SP; Commers J; Fahed R. "Is CRS & HIPEC a safe and effective palliative treatment strategy in patients with refractory symptomatic peritoneal metastasis?". Regional Cancer Therapies; 2013
 45. Foster JM; Subbiah SP; Commers J; Fahed R. "Outcomes of Untreated Stage IV Ovarian Cancer Patients Treated with HIPEC and One Case Treated with Synchronous HIPEC/HITOC". Regional Cancer Therapies; 2013
 46. Sleightholm RL; Watley D; Broekhuis J; Wahlmeier S; Foster JM. "Safety and outcomes of cytoreductive surgery and HIPEC in elderly patients with high PCI large volume

- peritoneal metastasis". Regional Cancer Therapies; 2014
47. Watley D; Sleightholm RL; Broekhuis J; Wahlmeier S; Foster JM. "HIPEC outcomes in OEC at index surgery, salvage, and palliative CRS/HIPEC", (oral). Regional Cancer Therapies; 2014
 48. Foster JM; Sleightholm RL; Watley D; Broekhuis J; Wahlmeier S. "Early identification of DPAM in 'at risk' MAN patients, a new approach to MAN surveillance", (poster). Regional Cancer Therapies; 2014
 49. Watley D; Sleightholm RL; Broekhuis J; Wahlmeier S; Foster JM. Defining the Safety of Epidural Pain Control in CRS/HIPEC in Conjunction with VTE Prophylaxis. Regional Cancer Therapies; 2014
 50. Sleightholm RL; Watley D; Broekhuis J; Wahlmeier S; foster jm. Defining the safety of epidural pain control in CRS/HIPEC in conjunction with VTE prophylaxis. SWSC Quick Shot Oral Presentation; 2014
 51. Watley D; Sleightholm RL; Broekhuis J; foster jm. HIPEC outcomes in OEC at index surgery, salvage, and palliative. SWSC Poster CRS/HIPEC; 2014
 52. Wahlmeier S; Sleightholm RL; Broekhuis J; foster jm. Early identification of DPAM in 'at risk' MAN patients a new approach to MAN surveillance. SWSC Poster; 2014
 53. Wahlmeier S; Sleightholm RL; Watley D; Broekhuis J; foster jm. Early identification of DPAM in 'at risk' MAN patients a new approach to MAN surveillance. Midwest Biomedical Student Research Forum; 2014
 54. Sleightholm RL; Watley D; Broekhuis J; Wahlmeier S; foster jm. Defining the safety of epidural pain control in CRS/HIPEC in conjunction with VTE prophylaxis. Midwest Student Biomedical Research Forum; 2014
 55. Broekhuis J; Sleightholm RL; Watley D; Wahlmeier S; foster jm. Safety and outcomes of cytoreductive surgery and HIPEC in elderly patients with high PCI large volume peritoneal metastasis. Southwest Surgical Congress (SWSC), (poster); 2014
 56. Watley D; Sleightholm RL; Broekhuis J; foster jm. HIPEC outcomes in OEC at index surgery, salvage, and palliative CRS/HIPEC. Midwest Student Biomedical Research Forum; 2014
 57. Broekhuis J; Sleightholm RL; Watley D; Wahlmeier S; foster jm. Safety and outcomes of cytoreductive surgery and HIPEC in elderly patients with high PCI large volume peritoneal metastasis. Midwest Student Biomedical Research Forum; 2014
 58. Patel A; kaur s; Sheinin Y; batra surinder k.; foster jm. Evaluation of Glycoprotein Expression Profiles in Peritoneal Metastases as a Potential Therapeutic Target. Regional Cancer Therapies; 2015
 59. Sleightholm RL; Watley D; Broekhuis J; Wahlmeier S; foster jm. Defining the safety of epidural pain control in CRS/HIPEC in conjunction with VTE prophylaxis, (poster). The American Physician Scientists Association (APSA); 2015
 60. Sleightholm RL; Watley D; Broekhuis J; Wahlmeier S; foster jm. Defining the safety of epidural pain control in CRS/HIPEC in conjunction with VTE prophylaxis, (poster). Regional Cancer Therapies; 2015
 61. Patel A; Cushman-Vokoun A; Sleightholm RL; Foster JM. Exploration of mutations in GI cancers with peritoneal metastasis. Regional Cancer Therapies 2015-2016, Oral Presentation; 2016
 62. Sleightholm RL; Burt J; Watley D; Wahlmeier S; foster jm. Reducing VTE Event Rates in Complex Abdominal Cancer Surgery: A Retrospective, Single Institute Retrospective

- Comparison of Dextran vs Heparin. ASCO 2015-2016; 2016
63. Cole, K; Britton, H; Ly, Q; Hollingsworth, T; Foster JM; Vargus, L; Padussis, J; Talmadge, J. Novel Adaptive Cellular Therapy using splenic CD8+ PD1+ cells for Pancreatic Adenocarcinoma Patients. NCI GI/Pancreatic SPOREs Meeting; Omaha, NE. 2018 Oct
64. Cole KE; Ly QP; Cox JL; Hollingsworth MA; Padussis JC; Foster JM; Vargus. Abstract 1420: Novel expansion of CD8+PD1+ spleen cells for therapeutic intent in pancreatic adenocarcinoma cancer. AACR Annual Meeting 2019; Atlanta, GA. Cancer Research. 2019 Jul
65. Cole KE; Ly QP; Cox JL; Hollingsworth MA; Padussis JC; Foster JM; Vargus Jr. LM. Abstract 4049: Cellular phenotypes of spleen cells in cancer patients targeted for adoptive cellular therapy. AACR Annual Meeting 2019; Atlanta, GA. Cancer Research. 2019 Jul , Vol. 79

H. PUBLISHED AUDIOVISUAL OR COMPUTER-BASED EDUCATIONAL MATERIALS AND COMPUTER SOFTWARE

Not Applicable

I. PUBLISHED CONTINUING EDUCATION MATERIALS

Not Applicable

J. EDITORIALS

Not Applicable

K. CONFERENCE PROCEEDING

Not Applicable